(CercleFinance.com) – DBV Technologies rises 2.8% to 17.8 euros, supported by Bryan Garnier initiates coverage on the title to “buy”, with an intrinsic value (‘fair value ‘) set at 27 euros, before a period of research and development planned on May 21
Intermediate considers that the biopharmaceutical company at a turning point, while Phase IIb data are expected in October for its flagship product, the Viaskin peanut.
‘potential blockbuster product and a wide range of applications for the platform should lead to the creation of value, whether on one basis or via a sale to a large pharmaceutical company, ‘he continues.
Copyright (c) 2014 CercleFinance.com. All rights reserved.
Follow this action? Get all info in real-time
No comments:
Post a Comment